...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>NMR in biomedicine >Improved multiparametric MRI discrimination between low-risk prostate cancer and benign tissues in a small cohort of 5-reductase inhibitor treated individuals as compared with an untreated cohort
【24h】

Improved multiparametric MRI discrimination between low-risk prostate cancer and benign tissues in a small cohort of 5-reductase inhibitor treated individuals as compared with an untreated cohort

机译：与未经处理的队列相比，在5级还原酶抑制剂治疗的个体中改善了低风险前列腺癌和良性组织之间的多级癌症和良性组织之间的歧视

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The purpose of this study was to determine whether 5-reductase inhibitors (5-ARIs) affect the discrimination between low-grade prostate cancer and benign tissues on multiparametric MRI (mpMRI). Twenty men with biopsy-proven Gleason 3+3 prostate cancer and 3T mpMRI were studied. Ten patients (Tx) had been receiving 5-ARIs for at least a year at scan time. Ten untreated patients (Un) were matched to the treated cohort. For each subject two regions of interest representing cancerous and benign tissues were drawn within the peripheral zone of each prostate, MR measures evaluated, and cancer contrast versus benign (contrast = (MRTumor-MRHealthy)/MRHealthy) calculated. Decreased cancer contrast was noted on T-2-weighted images: 0.4 (Un) versus 0.3 (Tx). However, for functional MR measures, a better separation of cancerous and benign tissues was observed in the treated group. Cancer contrast on high-b diffusion-weighted imaging (DWI) was 0.61 (Un) versus 0.99 (Tx). Logistic regression analysis yielded higher AUC (area under the curve) values for distinguishing cancerous from benign regions in treated subjects on high-b DWI (0.71 (Un), 0.94 (Tx)), maximal enhancement slope (0.95 (Un), 1 (Tx)), peak enhancement (0.84 (Un), 0.93 (Tx)), washout slope (0.78 (Un), 0.99 (Tx)), K-trans (0.9 (Un), 1 (Tx)), and combined measures (0.86 (Un), 0.99 (Tx)). Coefficients of variation for MR measures were lower in benign and cancerous tissues in the treated group compared with the untreated group. This study's results suggest an increase in homogeneity of benign and malignant peripheral zone prostatic tissues with 5-ARI exposure, observed as reduced variability of MR measures after treatment. Cancer discrimination was lower with T-2-weighted imaging, but was higher with functional MR measures in a 5-ARI-treated cohort compared with controls.
机译：本研究的目的是确定5-还原酶抑制剂（5- aris）是否影响低级前列腺癌和良性组织对多体MRI（MPMRI）的歧视。研究了二十名患有活组织检查验证的Gleason 3 + 3前列腺癌和3T MPMRI的男性。 10名患者（TX）在扫描时间至少每年接受5 aris。十个未经处理的患者（联合国）与治疗的队列相匹配。对于每个主题，在每个前列腺的周围区域内绘制了两种感兴趣区域，评估的MR措施和癌症对比（对比度=（MRTUMOR-MRECHEATHY）/ MREHEALTHY）计算。在T-2加权图像上注意到癌症对比度降低：0.4（UN）与0.3（Tx）。然而，对于功能性MR测量，在治疗组中观察到更好地分离癌变和良性组织。高B扩散加权成像（DWI）上的癌症对比为0.61（UN），而不是0.99（TX）。 Logistic回归分析产生更高的AUC（曲线下的区域）值，以区分癌症在高B DWI（0.71（UN），0.94（TX）），最大增强斜率（0.95（UN），1（ TX），峰值增强（0.84（UN），0.93（TX）），冲洗斜率（0.78（UN），0.99（TX）），K-Trans（0.9（UN），1（TX））和组合措施（0.86（UN），0.99（TX））。与未处理基团相比，治疗组中MR测量的变异系数较低，癌组织较低。该研究的结果表明，良性和恶性周围区域前列腺组织的均匀性增加，具有5- ari暴露，观察到治疗后MR措施的可变性。癌症歧视与T-2加权成像较低，但与对照相比，5- ari治疗的队列中的功能性MR测量较高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号